Defective Breast Mesh, Acellular Dermal Matrix, and Bioabsorbable Scaffold Injury Attorneys in California: The Complete Guide for Women, Families, and Survivors

If you are reading this in California, you may be navigating a medical crisis that feels as isolating as it is frightening. Whether you underwent a post-mastectomy reconstruction at a world-renowned center like the UCLA Jonsson Comprehensive Cancer Center or the Stanford Cancer Institute, or sought a cosmetic lift in Beverly Hills or Newport Beach, the physical betrayal of a failing medical device is a weight no woman should carry alone. We understand that behind every medical record is a person who placed her trust in a manufacturer’s promises, only to face infections, disfigurement, or a terrifying new diagnosis like BIA-ALCL.

Our firm, Attorney911, led by Managing Partner Ralph Manginello, has spent twenty-seven years fighting for the rights of the injured. We serve clients across the country in high-stakes federal product liability litigation, bringing a level of technical rigor that generalist personal injury firms cannot match. Alongside Lupe Peña, an associate attorney with a deep background in insurance defense and the ability to conduct full consultations in fluent Spanish, our team navigates the complications of medical device law to secure the compensation survivors need for revision surgeries and long-term care. If your reconstruction has failed or you have been diagnosed with a device-associated cancer in California, call us at 1-888-ATTY-911 for a confidential conversation about your path forward.

Understanding the Devices: What Was Implanted in Your Body?

In the world of California breast surgery, surgeons frequently use “reinforcement” materials to support an implant or expander. These products are often marketed as an “internal bra,” promising a more natural aesthetic or better support for the lower pole of the breast. However, many women in California were never told that the FDA has not actually cleared these products specifically for use in the breast.

Acellular Dermal Matrix (ADM)

Acellular Dermal Matrix is a biological tissue graft. Manufacturers take human-cadaver skin or animal skin (porcine or bovine) and strip away the cells, leaving behind a “scaffold” of collagen. The theory is that your own body will grow new tissue into this scaffold. Common ADM brands used in California hospitals include:

• AlloDerm and AlloDerm RTU (Allergan/AbbVie)
• Strattice (Allergan)
• FlexHD and FlexHD Pliable (MTF Biologics)
• AlloMax (C.R. Bard/Becton Dickinson)
• SurgiMend (Integra LifeSciences)

Bioabsorbable Scaffolds

Unlike permanent mesh, these synthetic products are designed to stay in your body for 18 to 24 months before dissolving. The most prominent material here is poly-4-hydroxybutyrate (P4HB).

• GalaFLEX Scaffold (Galatea Surgical/BD)
• Phasix Mesh (Bard/BD)
• DuraSorb (Integra)

The Manufacturers and the Profit Motive

The defendants in these cases are multi-billion-dollar corporations like Becton Dickinson (BD), which reported over $21 billion in revenue for 2025, and AbbVie (Allergan). These companies pushed their products into California operating rooms through aggressive off-label marketing, even when internal data and federal communications suggested that products like GalaFLEX and FlexHD carried elevated risks of infection and explantation.

The FDA Regulatory Failure: The 510(k) Pathway

One of the most shocking facts for patients in California is that most of these devices never underwent “approval” by the FDA. Instead, they reached the market through the 510(k) clearance pathway (21 CFR Part 807). This is a regulatory shortcut where a manufacturer only has to prove their device is “substantially equivalent” to a “predicate” device already on the market.

For example, the manufacturer of GalaFLEX cited a surgical suture as a predicate for its mesh. Under the 510(k) system, as long as the material is similar, the FDA may clear it without a single clinical trial in human breast tissue. As we often explain to our clients, this “predicate creep” allowed devices meant for hernia repair to be implanted in the breasts of California cancer survivors without adequate safety testing.

In November 2023, the FDA issued a definitive letter to healthcare providers across California and the nation, stating: “The safety and effectiveness of surgical mesh in breast surgery, including in augmentation or reconstruction, has not been determined by the FDA.” This admission is central to our litigation strategy. If the manufacturer knew the FDA hadn’t determined safety, yet they marketed the product to your California surgeon anyway, they may be liable for the resulting harm.

The Pathology of Injury: ALCL, SCC, and Red Breast Syndrome

When we examine a case at Attorney911, we look at the specific pathology reports. We understand the science because we have to. For a woman in California suffering after a reconstruction, the medical terminology can be overwhelming. We break it down into three primary categories of catastrophic harm.

BIA-ALCL (Breast Implant-Associated Anaplastic Large Cell Lymphoma)

This is not breast cancer; it is a T-cell lymphoma of the immune system. The World Health Organization has recognized it as a distinct malignancy since 2016. In California, we focus on the Allergan BIOCELL textured implants, which were recalled in July 2019. The pathology for ALCL usually shows:

• CD30 Positive
• ALK Negative
• T-cell receptor gene rearrangement

If you have felt a sudden swelling (seroma) or a mass 7 to 10 years after your surgery, you need a specialized biopsy. We are currently involved in the Allergan BIOCELL MDL 2921 in the District of New Jersey before Judge Brian R. Martinotti, where a bellwether trial is scheduled for October 19, 2026.

BIA-SCC (Breast Implant-Associated Squamous Cell Carcinoma)

This is an emerging and even more aggressive malignancy found in the scar tissue (capsule) around the implant. The FDA issued a safety communication in September 2022 and an update in March 2023 after identifying deaths associated with this tumor. Unlike ALCL, SCC is appearing in both smooth and textured implants, with a latency of up to 42 years.

Red Breast Syndrome and Endotoxin Science

Many California patients suffer from “Red Breast Syndrome” (RBS)—a bright redness of the skin over the ADM that looks like an infection but doesn’t respond to antibiotics. Research, including studies by Nguyen et al. (2019), suggest this is caused by endotoxins (bacterial remnants) left on the mesh like FlexHD or AlloMax during manufacturing. Even though the device is “sterile,” the endotoxins trigger a massive inflammatory response. If you had to have your ADM removed because it wouldn’t stop being red, the manufacturer’s quality control is the likely culprit.

Why Your California Case Needs Attorney911

The legal landscape of medical device injury is a battlefield of “preemption.” In many cases, if a device is fully approved by the FDA (PMA approval), federal law “preempts” or blocks state lawsuits. However, because most breast mesh and ADM products used in California were cleared through the 510(k) pathway, the landmark Supreme Court case Medtronic v. Lohr (1996) allows us to pursue state-law claims.

Generalist firms often miss the nuances of Parallel Claims. Under Riegel v. Medtronic (2008), we can successfully sue if we prove the manufacturer violated federal requirements—such as failing to report adverse events to the MAUDE database (21 CFR Part 803).

Our Firm’s Credentials

Ralph Manginello is not just an attorney; he is a member of the Pro Bono College of the State Bar of Texas, a distinction given to those who far exceed the bar’s service goals. Our firm has an Avvo Rating of 8.2 (Excellent) and a Martindale-Hubbell Preeminent 5.0 of 5.0 rating. We are also the firm of record in high-profile litigation like Bermudez v. Pi Kappa Phi, where we are seeking $10,000,000 for a victim of institutional negligence. This experience in complex, multi-defendant litigation is exactly what is needed to take on companies like Becton Dickinson or Johnson & Johnson.

The Lupe Peña Advantage

For the diverse communities in Los Angeles, San Diego, and the Central Valley, language should never be a barrier to justice. Lupe Peña conducts full client consultations in fluent Spanish. His background in insurance defense means he knows exactly how the other side will try to devalue your claim. He understands how to pierce the “learned intermediary” defense that manufacturers use to blame California surgeons for the manufacturer’s own failure to warn.

Whether you are in San Francisco, Sacramento, or Riverside, we are ready to listen. Call us at 888-ATTY-911 for a free consultation. If you prefer, hablamos español.

The Whistleblower: Dr. Hooman Noorchashm

The case against products like GalaFLEX and Phasix was significantly bolstered by Dr. Hooman Noorchashm, a former Medical Director at Becton Dickinson (BD). Dr. Noorchashm was reportedly terminated in 2022 after raising internal alarms about the safety of surgical mesh in breast surgery.

He alleged that BD withheld data about breast cancer recurrences in clinical trials and that the company participated in aggressive off-label marketing. This whistleblower record is a “Forced Surprise” for many patients—their own doctors may have been misled by a company that chose to silence its own Medical Director rather than protect women. At Attorney911, we integrate this investigative record into our litigation to show that the harm wasn’t a mistake—it was a corporate choice.

Damages: What a California Lawsuit Can Recover

If a defective mesh or ADM cost you your reconstruction, you aren’t just suing for a refund of the device. You are suing for the devastation of your quality of life. In California, we seek to recover:

• Past and Future Medical Expenses: This includes the cost of multiple revision surgeries, hyperbaric oxygen therapy, and infectious disease consults.
• Pain and Suffering: The emotional trauma of losing a breast reconstruction after surviving cancer is immeasurable.
• Permanent Disfigurement: Many of our clients are left with “flat closures” or severe breast asymmetry that requires complex autologous tissue flaps (like the DIEP or TRAM flap) to repair.
• Economic Loss: Lost wages during the months of recovery from multiple surgeries.

Under California’s Code of Civil Procedure § 335.1, you generally have two years from the point of injury to file a claim. However, the Discovery Rule is vital. If you only recently found out that your “infection” was actually a reaction to defective mesh, your clock may only start now. We can help you navigate these deadlines.

Frequently Asked Questions for California Patients

Is surgical mesh actually approved for breast surgery?
No. As the FDA stated in November 2023, no surgical mesh (including GalaFLEX or Phasix) has been cleared or approved specifically for breast reconstruction or augmentation. It is used “off-label.”

What if I don’t know the brand of my mesh?
This is a common hurdle. We can help you secure your operative reports and device implant stickers from California hospitals. Modern records are required to keep “lot numbers” that identify the exact device used.

How much does an attorney cost?
At Attorney911, we work on a contingency fee basis. This means there is no upfront cost for you. We only get paid if we recover money for you. If we don’t win, you don’t owe us an attorney fee. Case expenses may apply.

Can I sue even if I moved to California after my surgery?
Yes. Product liability claims can often be filed in the federal district where you currently live or where the manufacturer is located. With our admission to federal courts, we can handle these multi-state jurisdictional issues.

What is the difference between BIA-ALCL and Breast Implant Illness (BII)?
BIA-ALCL is a specific, biopsy-confirmed cancer. BII is a constellation of systemic symptoms (fatigue, joint pain, brain fog) that many women experience. We handle cases involving both, provided there is a documented link to the device’s failure or a failure to warn of these risks.

Take Action: Protect Your Rights in California

The manufacturers of these devices have teams of lawyers in high-rise offices in San Francisco and Los Angeles working to protect their profits. You deserve a team that is just as aggressive, just as technical, and significantly more dedicated to your well-being.

Your focus should be on your health—on the next follow-up with your surgeon at Cedars-Sinai or City of Hope. Our focus is on the law. We are currently accepting cases for women in California who have suffered from:

• Infection and explantation of FlexHD or AlloMax
• Failure of GalaFLEX to resorb
• BIA-ALCL or BIA-SCC diagnosis
• Reconstruction failure involving any ADM or Scaffold

Do not let a corporation’s silence become your own. Call Ralph Manginello and Lupe Peña at 1-888-ATTY-911 or 888-288-9911. Every case is unique, and past results do not guarantee future outcomes, but we promise to fight for the maximum recovery permitted under the law.

Esta información es para fines educativos y no constituye asesoramiento legal. Consulte con un abogado para su situación específica. Attorney911 brinda representación bilingüe en todo California.

Attorney911 | The Manginello Law Firm, PLLC
1177 West Loop South, Suite 1600, Houston, TX 77027
Admitted to the United States District Court for the Southern District of Texas
Handling Federal Medical Device Litigation Nationwide
1-888-ATTY-911